<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335098</url>
  </required_header>
  <id_info>
    <org_study_id>1605-137-765</org_study_id>
    <nct_id>NCT03335098</nct_id>
  </id_info>
  <brief_title>Study of VTD in Waldenstrom's Macroglobulinemia</brief_title>
  <acronym>BOMB-THROW</acronym>
  <official_title>A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the
      efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients
      with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>at 3 years</time_frame>
    <description>Overall response rate as per Lugano criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 3 years</time_frame>
    <description>Time from enrollment to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 3 years</time_frame>
    <description>Time from enrollment to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous bortezomib 1.3mg/m2 on days 1, 4, 8, and 11 (every 4 weeks, up to 6 cycles) Oral thalidomide 50mg daily on days 1-28 (every 4 weeks, up to 6 cycles) Intravenous or oral dexamethasone 40mg on days 1-4 (every 4 weeks, up to 6 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Six 4-week cycles</description>
    <arm_group_label>Study arm</arm_group_label>
    <other_name>Thalidomide</other_name>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 19 or older

          -  Newly diagnosed Waldenstrom's macroglobulinemia or lymphoplasmacytic lymphoma

          -  Previously untreated with chemotherapy

          -  ECOG performance status of 2 or lesser

          -  Peripheral blood white blood cell count ≥ 3,500/uL

          -  Peripheral blood neutrophil count ≥ 1,000/uL

          -  Peripheral blood platelet count ≥ 20,000/uL

          -  Peripheral blood hemoglobin ≥ 6.0g/dL

          -  Serum total bilirubin ≤ 2.0 mg/dL

          -  Serum aspartate aminotransferase ≤ 2.5 x (upper normal limit)

          -  Serum alanine aminotransferase ≤ 2.5 x (upper normal limit)

        Exclusion Criteria:

          -  Diagnosed with other malignancy within 5 years before enrollment

          -  Prior hematopoietic stem cell transplantation

          -  Prior organ transplantation

          -  Uncontrolled central nervous system involvement

          -  Congenital immunodeficiency

          -  Acquired immune deficiency syndrome (AIDS)

          -  Pregnancy

          -  Uncontrolled epilepsy

          -  Uncontrolled psychological disease

          -  Peripheral neuropathy of grade 3 or higher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eun-Hee Park, CRN</last_name>
    <phone>+82-10-3349-1453</phone>
    <email>eh.park@daum.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junghoon Shin, MD</last_name>
    <phone>+82-10-2015-4932</phone>
    <email>freeustand@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun-Jin Kim, CRC</last_name>
      <phone>+82-31-787-8226</phone>
      <email>r0638@snubh.org</email>
    </contact>
    <contact_backup>
      <last_name>Jeong-Ok Lee, MD</last_name>
      <phone>+82-31-787-7055</phone>
      <email>jeongok77@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-Hee Park, CRN</last_name>
      <phone>+82-10-3349-1453</phone>
      <email>eh.park@daum.net</email>
    </contact>
    <contact_backup>
      <last_name>Junghoon Shin, MD</last_name>
      <phone>+82-10-2015-4932</phone>
      <email>freeustand@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Junghoon Shin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngil Koh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Youngil Koh</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Waldenstrom's macroglobulinemia</keyword>
  <keyword>Lymphoplasmacytic lymphoma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD regarding participant demographics, study treatment, response, survival, and adverse events will be shared after publishment of the study results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

